AU2023231494A1 - Compositions comprising meai and n-acylethanolamines and uses thereof - Google Patents

Compositions comprising meai and n-acylethanolamines and uses thereof Download PDF

Info

Publication number
AU2023231494A1
AU2023231494A1 AU2023231494A AU2023231494A AU2023231494A1 AU 2023231494 A1 AU2023231494 A1 AU 2023231494A1 AU 2023231494 A AU2023231494 A AU 2023231494A AU 2023231494 A AU2023231494 A AU 2023231494A AU 2023231494 A1 AU2023231494 A1 AU 2023231494A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
meai
alcohol
certain embodiments
consumption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023231494A
Other languages
English (en)
Inventor
Adi Zuloff-Shani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clearmind Labs Corp
Original Assignee
Clearmind Labs Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clearmind Labs Corp filed Critical Clearmind Labs Corp
Publication of AU2023231494A1 publication Critical patent/AU2023231494A1/en
Assigned to CLEARMIND LABS CORP. reassignment CLEARMIND LABS CORP. Request for Assignment Assignors: Clearmind Medicine Inc.
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023231494A 2022-03-07 2023-03-06 Compositions comprising meai and n-acylethanolamines and uses thereof Pending AU2023231494A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263317257P 2022-03-07 2022-03-07
US63/317,257 2022-03-07
PCT/IB2023/052091 WO2023170552A1 (en) 2022-03-07 2023-03-06 Compositions comprising meai and n-acylethanolamines and uses thereof

Publications (1)

Publication Number Publication Date
AU2023231494A1 true AU2023231494A1 (en) 2024-09-05

Family

ID=85706794

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023231494A Pending AU2023231494A1 (en) 2022-03-07 2023-03-06 Compositions comprising meai and n-acylethanolamines and uses thereof

Country Status (9)

Country Link
US (1) US20250302773A1 (https=)
EP (1) EP4489741A1 (https=)
JP (1) JP2025508052A (https=)
CN (1) CN119212690A (https=)
AU (1) AU2023231494A1 (https=)
CA (1) CA3244360A1 (https=)
IL (1) IL315486A (https=)
MX (1) MX2024010596A (https=)
WO (1) WO2023170552A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120225185A (zh) * 2022-09-21 2025-06-27 克力迈医药公司 5-甲氧基-2-氨基茚满(“meai”)在用于治疗代谢综合征的方法中的用途
WO2025196662A1 (en) * 2024-03-20 2025-09-25 Clearmind Labs Corp. Compositions and methods for treating eating disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5114946A (en) 1987-06-12 1992-05-19 American Cyanamid Company Transdermal delivery of pharmaceuticals
US4818541A (en) 1987-08-19 1989-04-04 Schering Corporation Transdermal delivery of enantiomers of phenylpropanolamine
JP3342491B2 (ja) 1993-08-06 2002-11-11 ファルマシア・アンド・アップジョン・カンパニー 選択的ドーパミンｄ３リガンドとしての２−アミノインダン類
WO2005002524A2 (en) * 2003-07-02 2005-01-13 The Regents Of The University Of California COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES OF OLEOYLETHANOLAMIDE-LIKE COMPOUNDS AND MODULATORS OF PPARα
CN107406369B (zh) * 2014-12-09 2021-01-15 以西结·戈兰 放纵行为调节剂
ES2580508B1 (es) * 2016-04-11 2018-09-12 Servicio Andaluz De Salud Composiciones para la prevención y/o tratamiento de los trastornos por uso de alcohol.

Also Published As

Publication number Publication date
JP2025508052A (ja) 2025-03-21
CN119212690A (zh) 2024-12-27
EP4489741A1 (en) 2025-01-15
MX2024010596A (es) 2025-01-09
CA3244360A1 (en) 2023-09-14
US20250302773A1 (en) 2025-10-02
WO2023170552A1 (en) 2023-09-14
IL315486A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
JP7442095B2 (ja) ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法
US20250302773A1 (en) Compositions comprising meai and n-acylethanolamines and uses thereof
KR20180015126A (ko) 자폐증을 치료하기 위한 조성물 및 방법
WO2024166059A1 (en) Compositions comprising n,n-dimethyltryptamine, optionally in combination with n-acylethanolamines and uses thereof
EP1401424B1 (en) Carbamate compounds for use in preventing or treating psychotic disorders
EP4661857A1 (en) Compositions comprising lysergic acid diethylamide, optionally in combination with n-acylethanolamines and uses thereof
WO2024166058A1 (en) Compositions comprising psilocybin, optionally in combination with n-acylethanolamines and uses thereof
RU2464023C2 (ru) Лекарственное средство для лечения фибромиалгии
AU2023346372A1 (en) Use of 5-methoxy-2-aminoindan ("meai") in methods for treating metabolic syndrome
US20250325500A1 (en) Use of 5-methoxy-2-aminoindan ("meai") in methods for treating cocaine addiction
US12263155B2 (en) Combinations of monoamine oxidase inhibitors and serotonin receptor agonists and their therapeutic use
EP4665327A1 (en) Compositions comprising 3,4-methylenedioxymethamphetamine, optionally in combination with n-acylethanolamines, and uses thereof
WO2024201245A1 (en) Compositions comprising 5-methoxy-2-aminoindan for treatment of depression
WO2024171075A1 (en) Compositions comprising ibogaine, optionally in combination with n-acylethanolamines, and uses thereof

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: CLEARMIND LABS CORP.

Free format text: FORMER APPLICANT(S): CLEARMIND MEDICINE INC.